Lifecore FY2025 revenue $128.9M meets guidance; net loss $38.7M; guides transition period $74-76M

LIFECORE BIOMEDICAL, INC. DE

2025-FY EPS reported -$0.09 revenue$8,665,000

Q4 revenue $36.4M (-4% YoY); net loss $1.1M vs $7.1M loss; adj. EBITDA $9.1M vs $10.4M.
FY2025 revenue $128.9M (+0.5% YoY); net loss $38.7M vs $12.0M income; adj. EBITDA $19.5M vs $20.2M.
Signed nine new customer programs in FY2025; post-quarter added GLP-1 obesity therapy and Phase 2 dermatology programs.
Transition period (May-Dec 2025) guidance: revenue $74-76M; adj. EBITDA $12-14M; net loss $19.8-17.8M.
Moving fiscal year to calendar year-end Dec 31, 2025; new ERP system planned for Q1 2026.

item 2.02 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001005286-25-000106
form_type: 8-K
ticker: LFCR
cik: 0001005286
company_name: LIFECORE BIOMEDICAL, INC. DE
filed_at: 2025-08-07T23:59:59+00:00
discovered_at: 2026-05-14T18:02:43.114947+00:00
generated_at: 2026-05-17T16:57:42.859126+00:00
sec_items: ["2.02", "9.01"]
event_type: earnings
sentiment: negative
materiality_score: 0.8
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001005286-25-000106
json_url: https://secwatch.observer/filing/0001005286-25-000106.json
markdown_url: https://secwatch.observer/filing/0001005286-25-000106.md
text_url: https://secwatch.observer/filing/0001005286-25-000106.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1005286/000100528625000106/0001005286-25-000106-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1005286/000100528625000106/lndc-20250807.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0001005286-25-000106

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.